Here are the general guidelines and anatomical considerations we adhere to: Needle Length is Key: For injections in the cervical (neck) and upper thoracic (upper back) regions, we typically use a 30-gauge, 1-inch needle
Cannot redeclare control with same name "grid_2_section_content_quick_view"
Urgent need for safe dose escalation and tumor-selective approaches Despite its proven efficacy, the full potential of brachytherapy in cervical cancer is constrained by the delicate balance between tumor control and toxicity to adjacent organs [116, 117]
These peptides, which include glucose-dependent insulinotropic peptide (GIP) and GLP1, are responsible for the incretin effect, which explains why the stimulus for insulin release is stronger upon receiving an oral glucose load, rather than an intravenous one.40,41 Dipeptidyl peptidase 4 (DPP-4) is the protein that cleaves and inactivates GLP-1 and GIP in a few minutes,40 thus the medications that inhibit said aminopeptidase increase the circulating levels of the incretins, enabling the stimulation of glucose-dependent insulin secretion in the pancreatic islets, through membrane receptors in the cells, to persist.41 Sitagliptin, linagliptin, saxagliptin, vildagliptin, and alogliptin, among others, belong to the group of DPP-4 inhibitors (iDDP-4)
